“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report
20 June 2019
Visiongain has launched a new pharma report Top 25 Vaccines Market Forecast 2019-2029: Prevnar/Prevnar 13, Gardasil/Gardasil 9, Fluzone/Vaxigrip, Pentacel, Infanrix, Pediarix, GSK Hepatitis Vaccine, Pneumovax 23, Varivax, Bexsero, Boostrix, Menactra, RotaTeq, Rotarix, Zostavax, Synflorix, FluLaval/Fluarix, ProQuad, M-M-R II, Adacel, Menveo, Repevax, Cervarix, FSME/IMMUN-TicoVac, Ixiaro, FluMist/Fluenz.
Visiongain predicts that the overall global market, submarket and product revenues will continue to grow, with human vaccines driving the sales of pharmaceutical companies. The industry will see entry of new key players and advancements in technology, overall resulting in an increase in market size of the world human vaccines market.
The lead analyst of the report commented "There is an increasing focus to identify diseases that currently do not have a vaccine. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create new vaccines that are not already on the market. This prevents stagnation within the market and will help drive the growth of the human vaccines market.
The media is playing an increasingly important role in spreading awareness about the complications of various infectious diseases if the public is not immunized. The increasing levels of awareness has promoted the benefits of vaccines as the most effective form of immunization against infection, consequently leading to increased demand for the vaccines."
Leading companies featured in the report include AstraZeneca, Eli Lilly, Emergent BioSolutions Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Serum Institute of India Private Limited, Takeda and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Recent News
Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034
The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034
26 March 2024
Read
Visiongain Publishes Medical Imaging Devices Market Report 2024-2034
The global Medical Imaging Devices market was valued at US$ 54.3 billion in 2024 and is projected to grow at a CAGR of 4.6% during the forecast period 2024-2034.
20 March 2024
Read
Visiongain Publishes Women’s Health Market Report 2024-2034
The global Women’s Health market was estimated to be valued at US$ 61 billion in 2034 and is expected to register a CAGR of 4.6% from 2024 to 2034.
18 March 2024
Read
Visiongain Publishes Clinical Trial Supplies Market Report 2024-2034
The global Clinical Trial Supplies market is estimated at US$4,146.7 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period 2024-2034.